Stem Cell Therapy for Cerebral Palsy
Phase 1
Withdrawn
- Conditions
- Cerebral Palsy
- Interventions
- Procedure: Autologous bone marrow mononuclear cell transplantation
- Registration Number
- NCT01978821
- Lead Sponsor
- Neurogen Brain and Spine Institute
- Brief Summary
the purpose of this study was to study the effect of stem cell therapy on common symptoms of cerebral palsy patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Diagnosed cases of any type of Cerebral Palsy
- age above 12 months.
Exclusion Criteria
- presence of acute infections such as Human immunodeficiency virus/Hepatitis B Virus/Hepatitis C Virus
- malignancies
- bleeding tendencies
- pneumonia
- renal failure
- severe liver dysfunction
- severe anemia [Hemoglobin < 8]
- any bone marrow disorder
- space occupying lesion in brain
- other acute medical conditions such as respiratory infection and pyrexia.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description stem cell Autologous bone marrow mononuclear cell transplantation autologous bone marrow mononuclear cell transplantation
- Primary Outcome Measures
Name Time Method Change in clinical symptoms of cerebral palsy after 6 months Six months
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Neurogen brain and spine institute
🇮🇳Mumbai, Maharashtra, India